Study of pharmacokinetic of new peptide drug 1-deamino-arginine-vasotocin for hypernatremia correction
Authors
-
Vera M. Kosman
St.-Petersburg Institute of Pharmacy
https://orcid.org/0000-0001-9690-1935
-
Natalya M. Faustova
St.-Petersburg Institute of Pharmacy
https://orcid.org/0000-0002-6866-5741
-
Marina V. Karlina
St.-Petersburg Institute of Pharmacy
https://orcid.org/0000-0002-6292-8934
-
Valery G. Makarov
St.-Petersburg Institute of Pharmacy
https://orcid.org/0000-0002-2447-7888
-
Marina N. Makarova
St.-Petersburg Institute of Pharmacy
https://orcid.org/0000-0003-3176-6386
DOI:
https://doi.org/10.3897/rrpharmacology.8.71802Abstract
Introduction: The pharmacokinetics studies are some of the necessary parts of the drugs preclinical investigations. Pharmacokinetic properties of new peptide drug 1-deamino-arginine-vasotocin (dAVT) in the form of an injection solution for intravenous and intramuscular administration for hypernatremia correction were investigated.
Materials and methods: The study was carried out on male rats and rabbits with a single intravenous administration of the drug in three doses, a single intramuscular administration in one dose and multiple administration to rats in one dose. To determine natriiuretic peptide concentration in blood plasma, tissues, and excretes, assays based on a sodium level change measurement using a biochemical analyzer have been developed and validated. Pharmacokinetic parameters were calculated by the model-independent method of statistical moments.
Results and discussion: The pharmacokinetics of the drug was found to be linear after a single administration of dAVT drug in the dose range 3–10 μg/kg for rats and rabbits. The relative bioavailability of dAVT after intramuscular and intravenous administrations was more than 30%. After a biomarker content change, the active substance was intensively distributed into highly vascularized organs (spleen), the organs that provide metabolism and subsequent excretion (liver and kidneys), whereas it hardly reached moderately and weakly vascularized tissues (muscles, omentum). Less than 10% dAVT was excreted with urine; no dAVT was determined in feces; and repeated administration did not lead to its cumulation.
Conclusion: Pharmacokinetics parameters of new nonapeptide drug 1-deamino-arginine-vasotocin were evaluated after original analytical biomarker approach. The study included all main areas necessary to characterize the original drug pharmacokinetic.
Keywords:
1-deamino-arginine-vasotocin, solution for injection, parenteral administration, pharmacokinetics, rats, rabbits, plasma, sodium levelReferences
Bland M (2000) An Introduction to Medical Statistics (3rd Edn). UK, London, Oxford. Medical Publications, 422 рp.
Boldyrev AA (2008) Role of Na/K-pump in excitable tissues (re¬view). Journal of the Siberian Federal University. Biology [Zhurnal Sibirskogo Federal’nogo Universiteta. Seriya: Biologiya] 1(3): 206– 225. https://doi.org/10.17516/1997-1389-0265 [in Russian]
FDA, CDER, CVM (2018) Bioanalytical Method for Validation. USA, Guidance for Industry, 2018 pp.
SCEEMP [Scientific Centre for Expert Evaluation of Medicinal Products] (2013) Guidelines for the examination of medicines. Mos¬cow, Volume I. Griff and K, 6–44. [in Russian]
SCEEMP [Scientific Centre for Expert Evaluation of Medicinal Products] (2012) Guidelines for preclinical drug research. Part one. Moscow, Griff and K, 845–855. [in Russian]
EMA [European Medicines Agency] (2011) Guideline on Bioanalytical Method Validation. London, 23 pp.
EMA [European Medicines Agency] (2017) Guideline on Non-clinical and Clinical Development of Similar Biological Medicinal Products Containing Low-molecular-weight-heparins. London, 8 pp.
ICH [International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use] (1995) Harmonized Tripartite Guideline, Text on Validation of Analytical Procedures. Geneva, International Conference on Harmonization ICH Q2A, 10 pp.
ICH [ICH, FDA, CDER, CBER] (1996) Harmonized Tripartite Guideline, Validation of Analytical Procedure: Methodology. Geneva, International Conference on Harmonization ICH Q2B, 13 pp.
Karlina MV, Demchenko DV, Pozharitskaya ON, Shikov AN, Makarova MN, Makarov VG, Fomichev YS, Natochin YuV, Kutina AV, Karavashkina TA, Golosova DV (2016) Composition with desamino-arginine for parenteral introduction and methods for its production. Patent 2634272 C.10.08.2016. [in Russian]
Kashkin VA, Bagrov AY, Fedorova OV (2002) Marinobufagenin (MBG) suppression of ethanol-seeking behavior is associated with inhibition of brain cortex Na/K-ATPase in mice. European Neuropsychopharmacology 2(3): 217–223. https://doi.org/10.1016/s0924-977x(02)00026-3 [PubMed]
Kosman VM, Faustova NM, Karlina MV, Makarov VG, Makarova MN (2021) Use of biomarkers in pharmacokinetics studies of medicinal products of natural origin. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products [Vedomosti Nauchnogo Centra Ekspertizy Sredstv Medicinskogo Primeneniya] 11(1): 24–35. https://doi.org/10.30895/1991-2919-2021-11-1-24-35 [in Russian]
Kutina AV, Kuznetsova AA, Natochin YuV (2005) Cations in human blood serum. Advances in Physiological Sciences [Uspekhi Fiziologicheskikh Nauk] 36(3): 3–32. [PubMed] [in Russian]
Natochin JuV, Kanashkina TA, Shakhmatova EI, Bespalova ZD, Zhukovskij JuG (2007) Application of [desamino-1, isoleicine-3, frginine-8] vasopressin as means for increase in excretion of salts of sodium by kidney and strengthening of return selective absorption from kidney tubules in water-solvent blood. Patent RU 2342949 C1. 26.03.2007. [in Russian]
Natochin YuV, Kutina AV (2009) Novel approach to integrative renal functional characteristics in various types of diuresis. Nephrology [Nefrologiya] 13(3): 19–23. [in Russian]
Natochin YuV, Vilensky BC, Shustin VA (1996) Osmolality and ion concentration in liquor and serum in epilepsy and ischemic stroke. Journal of Neuropathology and Psychiatry [Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova] 5: 77–80. [PubMed] [in Russian]
Sheyman DA (2019) Patofiziologiya pochki (Renal pathophysiology). Moscow, Binom, 192 pp. [in Russian]
Zhang Y, Huo M, Zhou J, Xie S (2010) PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Computer Methods and Programs in Biomedicine 99(3): 306–314. https://doi.org/10.1016/j.cmpb.2010.01.007 [PubMed]
Русский
English
